pp 1-10 | Cite as

Understanding CGRP and Cardiovascular Risk

  • Eloísa Rubio-Beltrán
  • Antoinette Maassen van den BrinkEmail author
Part of the Handbook of Experimental Pharmacology book series


Increasing knowledge about the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has led to the development of antibodies against this peptide or its receptor. However, CGRP is widely expressed throughout the body, participating not only in pathophysiological conditions but also in several physiological processes and homeostatic responses during pathophysiological events. Therefore, in this chapter, the risks of long-term blockade of the CGRP pathway will be discussed, with focus on the cardiovascular system, as this peptide has been described to have a protective role during ischemic events, and migraine patients present a higher risk of stroke and myocardial infarction.


Cardiovascular safety CGRP CGRP (receptor) antibodies Migraine Myocardial infarction Stroke 


  1. Al-Rubaiee M, Gangula PR, Millis RM, Walker RK, Umoh NA, Cousins VM, Jeffress MA, Haddad GE (2013) Inotropic and lusitropic effects of calcitonin gene-related peptide in the heart. Am J Physiol Heart Circ Physiol 304:H1525–H1537Google Scholar
  2. Aubdool AA, Thakore P, Argunhan F, Smillie SJ, Schnelle M, Srivastava S, Alawi KM, Wilde E, Mitchell J, Farrell-Dillon K, Richards DA, Maltese G, Siow RC, Nandi M, Clark JE, Shah AM, Sams A, Brain SD (2017) A novel alphacalcitonin gene-related peptide analogue protects against end-organ damage in experimental hypertension, cardiac hypertrophy, and heart failure. Circulation 136:367–383Google Scholar
  3. Avilés-Rosas VH, Rivera-Mancilla E, Marichal-Cancino BA, Manrique-Maldonado G, Altamirano-Espinoza AH, Maassen Van Den Brink A, Villalón CM (2017) Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats. Br J Pharmacol 174:2001–2014Google Scholar
  4. Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, Serrano D, Lipton RB (2013) Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache 53:1278–1299Google Scholar
  5. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Piña IL, Reeves MJ, Rexrode KM, Saposnik G, Singh V, Towfighi A, Vaccarino V, Walters MR (2014) Guidelines for the prevention of stroke in women. Stroke 45:1545–1588Google Scholar
  6. Chai W, Mehrotra S, Jan Danser AH, Schoemaker RG (2006) The role of calcitonin gene-related peptide (CGRP) in ischemic preconditioning in isolated rat hearts. Eur J Pharmacol 531:246–253Google Scholar
  7. Chan KY, Edvinsson L, Eftekhari S, Kimblad PO, Kane SA, Lynch J, Hargreaves RJ, de Vries R, Garrelds IM, van den Bogaerdt AJ, Danser AH, Maassenvandenbrink A (2010) Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther 334:746–752Google Scholar
  8. Chang CL, Donaghy M, Poulter N (1999) Migraine and stroke in young women: case-control study. Br Med J 318:13–18Google Scholar
  9. Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, Vigneri S, Edvinsson L, Maassen Van Den Brink A, European Headache Federation School of Advanced Studies (2017) Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain 18:96Google Scholar
  10. Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, Mikol DD (2018) A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache 58:715–723Google Scholar
  11. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129:420–423Google Scholar
  12. Edvinsson L (2017) The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache 57(Suppl 2):47–55Google Scholar
  13. Edvinsson L, Linde M (2010) New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 376:645–655Google Scholar
  14. Edvinsson L, Delgado-Zygmunt T, Ekman R, Jansen I, Svendgaard NA, Uddman R (1990) Involvement of perivascular sensory fibers in the pathophysiology of cerebral vasospasm following subarachnoid hemorrhage. J Cereb Blood Flow Metab 10:602–607Google Scholar
  15. Edvinsson L, Mulder H, Goadsby PJ, Uddman R (1998) Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J Auton Nerv Syst 70:15–22Google Scholar
  16. Etminan M, Takkouche B, Isorna FC, Samii A (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. Br Med J 330:63Google Scholar
  17. Gangula PRR, Wimalawansa SJ, Yallampalli C (2002) Sex steroid hormones enhance hypotensive effects of calcitonin gene-related peptide in aged female rats. Biol Reprod 67:1881–1887Google Scholar
  18. Gao Y, Song J, Chen H, Cao C, Lee C (2015) TRPV1 activation is involved in the cardioprotection of remote limb ischemic postconditioning in ischemia-reperfusion injury rats. Biochem Biophys Res Commun 463:1034–1039Google Scholar
  19. Gennari C, Fischer JA (1985) Cardiovascular action of calcitonin gene-related peptide in humans. Calcif Tissue Int 37:581–584Google Scholar
  20. Gennari C, Nami R, Agnusdei D, Fischer JA (1990) Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure. Cardiovasc Res 24:239–241Google Scholar
  21. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine – current understanding and treatment. N Engl J Med 346:257–270Google Scholar
  22. Gulbenkian S, Opgaard OS, Ekman R, Andrade NC, Wharton J, Polak JM, Queiroz e Melo J, Edvinsson L (1993) Peptidergic innervation of human epicardial coronary arteries. Circ Res 73:579–588Google Scholar
  23. Holland PR, Goadsby PJ (2018) Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics 15:304–312Google Scholar
  24. Homma S, Kimura T, Sakai S, Yanagi K-I, Miyauchi Y, Aonuma K, Miyauchi T (2014) Calcitonin gene-related peptide protects the myocardium from ischemia induced by endothelin-1: intravital microscopic observation and 31P-MR spectroscopic studies. Life Sci 118:248–254Google Scholar
  25. Humphries KH, Pu A, Gao M, Carere RG, Pilote L (2008) Angina with “normal” coronary arteries: sex differences in outcomes. Am Heart J 155:375–381Google Scholar
  26. Inoue T, Shimizu H, Kaminuma T, Tajima M, Watabe K, Yoshimoto T (1996) Prevention of cerebral vasospasm by calcitonin gene-related peptide slow-release tablet after subarachnoid hemorrhage in monkeys. Neurosurgery 39:984–990Google Scholar
  27. Jianping L, Kevin AC, Donald JD, Scott CS (2013) Renal protective effects of α-calcitonin gene-related peptide in deoxycorticosterone-salt hypertension. Am J Physiol Renal Physiol 304:F1000–F1008Google Scholar
  28. Juul R, Edvinsson L, Gisvold SE, Ekman R, Brubakk AO, Fredriksen TA (1990) Calcitonin gene-related peptide-LI in subarachnoid haemorrhage in man. Signs of activation of the trigemino-cerebrovascular system? Br J Neurosurg 4:171–179Google Scholar
  29. Juul R, Aakhus S, Björnstad K, Gisvold SE, Brubakk AO, Edvinsson L (1994) Calcitonin gene-related peptide (human α-CGRP) counteracts vasoconstriction in human subarachnoid haemorrhage. Neurosci Lett 170:67–70Google Scholar
  30. Kaski JC, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA, Rosano GMC (1995) Cardiac syndrome X: clinical characteristics and left ventricular function: long-term follow-up study. J Am Coll Cardiol 25:807–814Google Scholar
  31. Keith IM, Tjen-A-Looi S, Kraiczi H, Ekman R (2000) Three-week neonatal hypoxia reduces blood CGRP and causes persistent pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 279:H1571–H1578Google Scholar
  32. Kurth T, Schürks M, Logroscino G, Buring JE (2009) Migraine frequency and risk of cardiovascular disease in women. Neurology 73:581–588Google Scholar
  33. Labastida-Ramirez A, Rubio-Beltran E, Villalon CM, MaassenVanDenBrink A (2017) Gender aspects of CGRP in migraine. Cephalalgia 333102417739584Google Scholar
  34. Lei J, Zhu F, Zhang Y, Duan L, Lei H, Huang W (2016) Transient receptor potential vanilloid subtype 1 inhibits inflammation and apoptosis via the release of calcitonin gene-related peptide in the heart after myocardial infarction. Cardiology 134:436–443Google Scholar
  35. Lindstedt IH, Edvinsson ML, Evinsson L (2006) Reduced responsiveness of cutaneous microcirculation in essential hypertension – a pilot study. Blood Press 15:275–280Google Scholar
  36. Liu Z, Liu Q, Cai H, Xu C, Liu G, Li Z (2011) Calcitonin gene-related peptide prevents blood–brain barrier injury and brain edema induced by focal cerebral ischemia reperfusion. Regul Pept 171:19–25Google Scholar
  37. Maassen van den Brink A, Rubio-Beltrán E, Duncker D, Villalón CM (2018) Is CGRP receptor blockade cardiovascularly safe? Appropriate studies are needed. Headache 58:1257–1258Google Scholar
  38. MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37:779–788Google Scholar
  39. Mai TH, Wu J, Diedrich A, Garland EM, Robertson D (2014) Calcitonin gene-related peptide (CGRP) in autonomic cardiovascular regulation and vascular structure. J Am Soc Hypertens 8:286–296Google Scholar
  40. McCulloch J, Uddman R, Kingman TA, Edvinsson L (1986) Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci 83:5731–5735Google Scholar
  41. Mieres JH, Gulati M, Merz NB, Berman DS, Gerber TC, Hayes SN, Kramer CM, Min JK, Newby LK, Nixon JV, Srichai MB, Pellikka PA, Redberg RF, Wenger NK, Shaw LJ (2014) Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease. Circulation 130:350–379Google Scholar
  42. Mitsikostas DD, Reuter U (2017) Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 30:272–280Google Scholar
  43. Moskowitz MA, Sakas DE, Wei EP, Kano M, Buzzi MG, Ogilvy C, Kontos HA (1989) Postocclusive cerebral hyperemia is markedly attenuated by chronic trigeminal ganglionectomy. Am J Physiol 257:H1736–H1739Google Scholar
  44. Negro A, Lionetto L, Simmaco M, Martelletti P (2012) CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 21:807–818Google Scholar
  45. Opgaard OS, Gulbenkian S, Bergdahl A, Barroso CP, Andrade NC, Polak JM, Queiroz e Melo JQ, Edvinsson L (1995) Innervation of human epicardial coronary veins: immunohistochemistry and vasomotility. Cardiovasc Res 29:463–468Google Scholar
  46. Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94:1099Google Scholar
  47. Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A (2013) Migraine and hemorrhagic stroke: a meta-analysis. Stroke 44:3032–3038Google Scholar
  48. Sakas DE, Moskowitz MA, Wei EP, Kontos HA, Kano M, Ogilvy CS (1989) Trigeminovascular fibers increase blood flow in cortical gray matter by axon reflex-like mechanisms during acute severe hypertension or seizures. Proc Natl Acad Sci 86:1401–1405Google Scholar
  49. Schebesch K-M, Herbst A, Bele S, Schödel P, Brawanski A, Stoerr E-M, Lohmeier A, Kagerbauer SM, Martin J, Proescholdt M (2013) Calcitonin-gene related peptide and cerebral vasospasm. J Clin Neurosci 20:584–586Google Scholar
  50. Scher AI, Terwindt GM, Picavet HSJ, Verschuren WMM, Ferrari MD, Launer LJ (2005) Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 64:614–620Google Scholar
  51. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. Br Med J 339:b3914Google Scholar
  52. Schuster NM, Vollbracht S, Rapoport AM (2015) Emerging treatments for the primary headache disorders. Neurol Sci 36(Suppl 1):109–113Google Scholar
  53. Smillie S-J, Brain SD (2011) Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides 45:93–104Google Scholar
  54. Smillie S-J, King R, Kodji X, Outzen E, Pozsgai G, Fernandes E, Marshall N, de Winter P, Heads Richard J, Dessapt-Baradez C, Gnudi L, Sams A, Shah Ajay M, Siow Richard C, Brain Susan D (2014) An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension 63:1056–1062Google Scholar
  55. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123:612–624Google Scholar
  56. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, Ansha MG, Barac A, Bensenor IM, Doan LP, Edessa D, Endres M, Foreman KJ, Gankpe FG, Gopalkrishna G, Goulart AC, Gupta R, Hankey GJ, Hay SI, Hegazy MI, Hilawe EH, Kasaeian A, Kassa DH, Khalil I, Khang Y-H, Khubchandan J, Kim YJ, Kokubo Y, Mohammed MA, Moradi-Lakeh M, Nguyen HLT, Nirayo YL, Qorbani M, Ranta A, Roba KT, Safiri S, Santos IS, Satpathy M, Sawhney M, Shiferaw MS, Shiue I, Smith M, Szoeke CEI, Truong NT, Venketasubramanian N, Weldegwergs KG, Westerman R, Wijeratne T, Tran BX, Yonemoto N, Feigin VL, Vos T, Murray CJL (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954–976Google Scholar
  57. Tepper SJ (2018) History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache 58(Suppl 3):238–275Google Scholar
  58. Tzourio C, Tehindrazanarivelo A, Iglesias S, Alperovitch A, Chedru F, d’Anglejan-Chatillon J, Bousser M-G (1995) Case-control study of migraine and risk of ischaemic stroke in young women. Br Med J 310:830–833Google Scholar
  59. Uddman R, Edvinsson L, Ekblad E, Håkanson R, Sundler F (1986) Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 15:1–23Google Scholar
  60. Valdemarsson S, Edvinsson L, Hedner P, Ekman R (1990) Hormonal influence on calcitonin gene-related peptide in man: effects of sex difference and contraceptive pills. Scand J Clin Lab Invest 50:385–388Google Scholar
  61. Vanmolkot FH, Van Bortel LM, de Hoon JN (2007) Altered arterial function in migraine of recent onset. Neurology 68:1563–1570Google Scholar
  62. Wang LH, Zhou SX, Li RC, Zheng LR, Zhu JH, Hu SJ, Sun YL (2012) Serum levels of calcitonin gene-related peptide and substance P are decreased in patients with diabetes mellitus and coronary artery disease. J Int Med Res 40:134–140Google Scholar
  63. Wang Z, Martorell BC, Wälchli T, Vogel O, Fischer J, Born W, Vogel J (2015) Calcitonin gene-related peptide (CGRP) receptors are important to maintain cerebrovascular reactivity in chronic hypertension. PLoS One 10:e0123697Google Scholar
  64. Wimalawansa SJ, MacIntyre I (1988) Calcitonin gene-related peptide and its specific binding sites in the cardiovascular system of rat. Int J Cardiol 20:29–37Google Scholar
  65. Wrobel Goldberg S, Silberstein SD (2015) Targeting CGRP: a new era for migraine treatment. CNS Drugs 29:443–452Google Scholar
  66. Yadav S, Yadav YS, Goel MM, Singh U, Natu SM, Negi MPS (2014) Calcitonin gene- and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case-control study. Arch Gynecol Obstet 290:897–903Google Scholar
  67. Zhang J-Y, Yan G-T, Liao J, Deng Z-H, Xue H, Wang L-H, Zhang K (2011) Leptin attenuates cerebral ischemia/reperfusion injury partially by CGRP expression. Eur J Pharmacol 671:61–69Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Eloísa Rubio-Beltrán
    • 1
  • Antoinette Maassen van den Brink
    • 1
    Email author
  1. 1.Division of Vascular Medicine and Pharmacology, Department of Internal MedicineErasmus Medical CenterRotterdamThe Netherlands

Personalised recommendations